EGFR and non-small cell lung carcinoma: In the cost-effectiveness analysis, we comprehensively evaluated the benefit of adjuvant EGFR-TKI application for early-stage EGFR mutation-positive NSCLC patients by synthesizing clinical survival data, quality of life and cost parameters.